Olezarsen Sodium

Summary

Olezarsen Sodium (CHEMBL4650263) is an approved oligonucleotide; indicated across 2 conditions including cardiovascular disorder and hypertriglyceridemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligonucleotide
• Indications: 2 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650263
Name	Olezarsen Sodium
Type	Oligonucleotide
Max phase	4

Also known as: AKCEA-APOCIII-LRx sodium, IONIS- APOCIII-LRx sodium, IONIS-APOCIII-LRX, SODIUM, ISIS 678354 sodium, ISIS-678354 SODIUM, Olezarsen sodium, Olpasiran sodium, Tryngolza, OLEZARSEN SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	1	MONDO:0004995	EFO:0000319
hypertriglyceridemia	1	MONDO:0005347	EFO:0004211

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).